BioCare Manufacturing is an emerging local manufacturing company setting up Malaysia’s first Asthama prevalent Metered Dose Inhaler manufacturing plant in Bandar Seri Iskandar, Perak. This is first of its kind state of art manufacturing facility. BioCare Manufacturing will also set up ophthalmic, nasal spray, dry powder inhaler and pre – filled syringe manufacturing facility.
BioCare Manufacturing was awarded EPP3 status by the Steering Committee chaired by Minister of Health and Minister in Prime Minister Department (CEO of PEMANDU) on December 2013.
As part of Malaysia’s National Transformation Programme, Economic Transformation Programme (ETP) was formulated to elevate our country to develop into high income nation status by 2020. ETP’s targets for 2020 will be achieved through implementation of 12 National Key Economic Areas (NKEAs), representing economic sectors which account for significant contributions to GNI. Hence, Entry Point Projects (EPP) are high impact projects, matched with specific ideas and actions, to spur the growth of the NKEAs.
BioCare being a EPP 3 status holder, complies with the Malaysian government’s initiative to enhance the usage of locally manufactured products in all governments’ procurement as well as creates a platform to expedite the necessary approvals and an off-take of MOH Tender.
Technology Partnership
Beximco Pharmaceutical is a subsidiary of a larger Beximco Group, a diversified conglomerate having 25 companies with group turnover of around USD 1 bn.
Beximco was incorporated in 1976 and started its manufacturing operation in 1980 with products under licenses of Bayer AG of Germany and Upjohn Inc. of USA.
Beximco is a leading pharmaceuticals players and largest exporter of medicine in the country having its global footprint in more than 50 countries.
Currently Beximco produces more than 300 generics in over 500 different strengths and dosages with highest number of international GMP accreditation in the country as well as US FDA approval.
Beximco manufacturing site is spread across 22 acre – area located in Dhaka, Bangladesh and involved in manufacturing tablets, inhalers, eye drops, IV fluid, ophthalmic, nasal spray and etc with sales of USD 130 million and had a market cap of USD 266mn in Dhaka Stock Exchanges (03/03/2014).
Beximco Pharma is among the very few companies in the world who successfully converted CFC based formulations to ozone friendly HFA Inhalers.
BPL is now the single largest producer of metered dose inhalers (MDI) in Bangladesh, and the only company to contract manufacture inhaler products for GSK.
Experience in marketing MDI product
BioCare Manufacturing and Beximco Pharmaceutical engage in technology and manufacturing collaboration to launch Chlorofluorocarbon (CFC) free Budesonide MDI in Malaysia. Beximco Pharma is among the very few companies in the world who successfully converted CFC based formulations to ozone friendly HFA Inhalers. BioCare would be engaging the Pressurized Metered Dose Inhaler Technology to manufacture CFC free MDI.
Pressurized Metered Dose Inhaler (pMDI) is a device that delivers a specific amount of medication to the lungs, in the form of short bursts of aerosolized medicine that is inhaled by the patients. It is the most commonly used Inhalation drug delivery and is used in the treatment of the respiratory tract diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD).
A metered dose inhaler consists of three major components;
1. Canisters: Produced of aluminium or stainless steel by means of deep drawing where the formulation resides.
2. Metering valve: Allows a metered quantity of the formulation to be dispensed with each actuation.
3. Actuator or mouthpiece: Allows the patient to operate the device and directs the aerosol into the lungs.
BioCare Pharmaceutical, one of the subsidiary company, has successfully bidded and secured four consecutive tenders spanning over 12 years with the latest awarded in June 2014 for the “Budesonide MDI “ under the Malaysian Ministry of Health’ “Approved Pharmaceutical Product List “ with average value of RM21 Million.
BioCare currently represents leading MDI generic manufacturers and suppliers such Beximco & Glenmark Pharmaceuticals in Malaysia.